KCT0003213
Completed
未知
A clinical trial to evaluate the pharmacokinetics ans safety of NVP-1402 compared with Exelon capsule in healthy male subjects
avipharm0 sites38 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- avipharm
- Enrollment
- 38
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Healthy adult male volunteers aged 19years old at screening
- •2\)Body weight ? 50 kg within the range of ± 20% of the calculated ideal body weight (IBW)
- •? IBW(kg) \= {height (cm) – 100} x 0\.9
- •3\)Without any congenital or chronic diseases requiring treatment, any pathological symptoms, or any abnormal findings on medical examination
- •4\)Subjects evaluated eligible for the study based on the screening test results such as laboratory tests including serology, hematology, blood chemistry, and urinalysis, etc. and electrocardiogram(ECG).
- •5\)Subjects who signed on the written informed consent form and comply with study requirements after listening and fully understanding the details of this study.
Exclusion Criteria
- •1\) Subjects with hypersensitivity to the active ingredients or other components of the investigational product(s) or medical history of significant hypersensitivity to other drugs or any additive(s).
- •2\) Subjects with medical history to affect absorption, distribution, metabolism and elimination of drug(s) (disease(s) of hepatic/biliary, renal, cardiovascular, endocrine (hypothyroidism etc.), respiratory, digestive, hematologic, central nervous, psychiatric, musculoskeletal systems, etc.)
- •3\) Subjects with active liver disease or alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels \>1\.5 times the upper limit of the normal range
- •4\) Subjects with creatinine clearance \<80 mL/min (Creatinine clearance calculated by Cockcroft\-Gault’s formula using serum creatinine).
- •5\) Subjects with gastrointestinal disease (Crohn's disease, active peptic ulcer disease, etc.) that would affect absorption of investigational products or history of gastrointestinal surgery (except for simple appendectomy or hernia surgery)
- •6\) Subjects with serious harms, surgical procedures or suspected symptoms of acute disease(s) (severe infection, severe injury, etc.) within 4 weeks prior to the first administration.
- •7\) Subjects who continued excessive drinking alcohol (\>21 units/week, 1unit\=10g\=12\.5 mL of pure alcohol) or could not abstain from alcohol since 3 days before the day to conduct the study or excessive smokers (\> 10 cigarettes /day).
- •8\) History of Substance abuse
- •9\) Ingesting any prescription drug(s) or herbal medicine(s) within 2 weeks prior to the first administration or any over\-the\-counter (OTC) drug(s) judged by the investigator to affect this study or the safety of the study subjects.
- •10\) Subjects who participated in any other study within 3 months prior to the first administration (the end of the previous study is determined as the last day of administration).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin CaDiseases of the circulatory systemKCT0001258Hanlim Pharmaceutical40
Completed
Not Applicable
A clinical study to evaluate the pharmacokinetics of colistin and to explore biomarkers for nephrotoxicity in healthy volunteersKCT0005944Kyung Hee University Hospital12
Recruiting
Not Applicable
Clinical trial to assess the pharmacokinetic characteristics of Lodivixx tab. 5/160mg in healthy male subjectsDiseases of the circulatory systemKCT0000710Hanlim Pharmaceutical60
Recruiting
Not Applicable
Clinical trial to assess the pharmacokinetic characteristics of Lodivixx tab. 5/160mg in healthy male subjectsDiseases of the circulatory systemKCT0000489Hanlim Pharmaceutical40
Active, not recruiting
Not Applicable
Clinical trial to assess the pharmacokinetic/Pharmacodynamic characteristics and safety/tolerability of CKD-519 new formulation in healthy male subjectsEndocrine, nutritional and metabolic diseaseKCT0001729Chong Kun Dang30